+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 165 Actively Recruiting clinical trials

R

Actively Recruiting

Researchers are collecting real-world data to assess how well Teleflexs vascular access devices perform and how safe they are when used as intended. These devices include various types such as central venous access devices, midline catheters, peripheral catheters, hemodialysis catheters, and arterial catheters with navigation and tip confirmation features. Some of these devices also have properties to reduce infections and blood clots. The study observes patients who need a vascular access device for therapy or diagnosis. It includes a variety of devices and accessories used for their placement and maintenance. The registry tracks the use and performance of these devices without assigning specific treatments, focusing instead on collecting data from routine clinical use. Participants will be monitored for device-related outcomes including the success of device use without removal due to adverse events within seven days after device removal. The study also evaluates how accurately catheter tip locations are verified immediately after removal. Data collection includes monitoring any device-related adverse events during this period. The trial will continue until December 2034, providing extended observation of device performance and safety.

All AgesAll Genders
3 locations
C

Actively Recruiting

Researchers are evaluating the efficacy and safety of rilvegostomig compared to pembrolizumab, both combined with platinum-based doublet chemotherapy, as a first-line treatment for patients with locally advanced or metastatic non-squamous non-small cell lung cancer NSCLC whose tumors express PD-L1 at 1% or higher. This Phase III, randomized, double-blind, global study focuses on patients without certain genetic mutations who have advanced disease not suitable for curative treatment. The trial aims to provide new treatment options for this patient group by comparing two immunotherapy approaches combined with chemotherapy. Participants receive either rilvegostomig or pembrolizumab, each given intravenously on Day 1 of every 21-day cycle, alongside platinum-based doublet chemotherapy carboplatin or cisplatin for up to four cycles. After chemotherapy, patients continue with maintenance monotherapy of their assigned immunotherapy rilvegostomig or pembrolizumab plus pemetrexed given intravenously on Day 1 of each 21-day cycle. This treatment continues until disease progression or unacceptable toxicity. Throughout the study, participants undergo regular assessments including tumor measurements by CT or MRI scans, organ and bone marrow function tests, and monitoring for side effects. Researchers will measure overall survival and progression-free survival for up to approximately six years. Patient-reported outcomes on physical functioning, quality of life, and lung cancer symptoms are also collected. Safety and pharmacokinetics of rilvegostomig are monitored to understand treatment effects and tolerability over the long term.

Age: 18Years +All GendersPhase 3
301 locations
G

Actively Recruiting

Researchers are evaluating the safety and effectiveness of rilvegostomig combined with platinum-based chemotherapy compared to pembrolizumab combined with the same chemotherapy for first-line treatment of patients with locally advanced or metastatic squamous non-small cell lung cancer mNSCLC whose tumors express PD-L1. This Phase III, randomized, double-blind study involves participants whose tumors have a PD-L1 expression of 1% or higher. Participants receive either rilvegostomig or pembrolizumab intravenously on Day 1 of each 21-day cycle, combined with carboplatin and paclitaxel or nab-paclitaxel chemotherapy. Chemotherapy is given for up to 4 cycles, with nab-paclitaxel administered on Days 1, 8, and 15 of each cycle. After the chemotherapy cycles, participants continue with the assigned drug alone. Throughout the study, researchers monitor overall survival and progression-free survival for up to approximately six years. Additional assessments include response rates, duration of response, drug levels in the body, immune reactions to rilvegostomig, and patient-reported physical functioning, quality of life, and lung cancer symptoms. Participants undergo regular evaluations to assess these outcomes and safety throughout the study period.

Age: 18Years +All GendersPhase 3
333 locations
L

Actively Recruiting

Researchers are evaluating the long-term safety and effects of vedolizumab given as a subcutaneous injection in children and teenagers aged 2 to 17 years who have moderate to severe active ulcerative colitis or Crohns disease. The study aims to understand any medical problems related to the treatment, the time until hospital visits due to bowel inflammation are needed, and the impact on quality of life. This is a phase 3b extension study involving participants from a previous trial who responded well or did not respond to vedolizumab treatment. Participants who responded well in the previous study will continue to receive vedolizumab subcutaneously either via a prefilled syringe with an autoinjector pen or with a needle safety device. Dosage depends on weight, with injections given every two or four weeks for up to 120 weeks or until the treatment becomes commercially available or the study ends. Those who did not respond well or recently used corticosteroids will not receive the drug but will be followed for approximately two years as an observational group. Throughout the study, participants will visit their clinic multiple times for safety monitoring and assessments. Researchers will track adverse events and serious side effects up to 18 weeks after the last dose, as well as other safety events in the observational group. They will also measure the time to major inflammatory bowel disease events and changes in quality of life using questionnaires. The total participation time can be up to two years from the first dose.

Age: 2Years - 17YearsAll GendersPhase 3
47 locations
A

Actively Recruiting

Researchers are studying the use of unlicensed cryopreserved cord blood units CBUs for transplantation in both children and adults with blood cancers and other related disorders. This observational study involves patients with hematologic malignancies and various inherited and acquired disorders affecting the blood and immune system. The main goal is to monitor how well neutrophil recovery occurs after transplantation using these unlicensed CBUs in multiple institutions. Participants receive unlicensed cryopreserved CBUs as part of their transplant treatment. The study includes patients of any age receiving these CBUs for approved indications. The protocol focuses on the access and distribution of these unlicensed units rather than a specific treatment intervention. The study gathers data from recipients who receive these CBUs, tracking outcomes after transplantation. Participants are monitored for neutrophil recovery at 60 and 100 days after transplant, defined by a neutrophil count of at least 500mm3. Researchers also collect information on infection transmission, infusion reactions, survival rates at one year, and incidence of acute and chronic graft versus host disease. Platelet recovery is also evaluated. Safety and efficacy outcomes are followed over time to better understand the effects of unlicensed CBUs in this patient population.

All AgesAll Genders
142 locations
P

Actively Recruiting

Researchers are evaluating tabelecleucel, an allogeneic T-cell immunotherapy, for treating Epstein-Barr virus-associated post-transplant lymphoproliferative disease EBV PTLD in patients after failure of rituximab or rituximab plus chemotherapy. This phase 3, multicenter, open-label trial focuses on participants who have undergone solid organ transplant or allogeneic hematopoietic cell transplant and whose disease has not responded to prior standard treatments. Participants receive intravenous tabelecleucel in 5-week cycles, with doses given on Days 1, 8, and 15 of each cycle, followed by observation through Day 35. Treatment continues until the participant achieves a maximal response, experiences unacceptable side effects, starts other therapies, or fails the tabelecleucel treatment. The study includes different cohorts based on transplant type and prior therapies, and all participants have confirmed availability of partially HLA-matched tabelecleucel. Throughout the study, participants undergo assessments including PET-CT or MRI scans to evaluate disease status, with additional brain imaging if central nervous system involvement exists. Researchers monitor response rates, duration of response, overall survival, and safety events such as allograft loss or rejection over a follow-up period of up to five years. Participants are observed closely to understand the benefits and risks of tabelecleucel in this condition.

All AgesAll GendersPhase 3
71 locations
E

Actively Recruiting

Researchers are evaluating the effects of three different doses of AZD8965 compared to a placebo in adults aged 40 and older with Idiopathic Pulmonary Fibrosis IPF. This Phase IIb study aims to assess how well AZD8965 works, its safety, and how well participants tolerate it. Participants include those on stable doses of approved antifibrotic therapies and those not receiving such treatments. Participants will be randomly assigned to one of four groups placebo, low dose, medium dose, or high dose of AZD8965. The study lasts 24 weeks and is conducted globally at approximately 200 sites. This is a double-blind, placebo-controlled, parallel-group study, meaning neither participants nor researchers know which treatment any participant receives during the trial. During the study, participants will have their lung function measured by changes in forced vital capacity FVC at 24 weeks, along with monitoring for safety through the recording of adverse events. Additional assessments include examining the relationship between dose and efficacy, rate of lung function decline, and pharmacokinetics of AZD8965. The total participation time is 24 weeks with safety follow-up up to 25 weeks.

Age: 40Years +All GendersPhase 2
198 locations
P

Actively Recruiting

Researchers are evaluating AZD0780, an oral PCSK9 inhibitor, in a phase 3 randomized, double-blind, placebo-controlled study to assess its effect on reducing major adverse cardiovascular events in patients with established atherosclerotic cardiovascular disease ASCVD or those at high risk for a first ASCVD event. The study compares AZD0780 with a placebo and is event-driven, focusing on time to first cardiovascular events over approximately 54 months. Participants will be randomly assigned to receive either oral AZD0780 once daily or a matching placebo once daily. The study treatment continues from randomization until the primary analysis censoring date, followed by a study closure visit which marks the final visit for each participant. Background lipid-lowering therapy is maintained and expected to achieve significant LDL cholesterol reduction. The study design includes parallel treatment groups with quadruple masking to ensure unbiased results. During the study, participants attend regular visits for monitoring and assessments over a period that can last up to about 54 months. Researchers will measure the time to first major cardiovascular events including heart attack, stroke, urgent coronary revascularization, cardiovascular death, and other related outcomes. Safety and efficacy are carefully monitored through clinical evaluations, laboratory tests, and patient follow-up until study completion.

Age: 18Years +All GendersPhase 3
1452 locations
E

Actively Recruiting

Researchers are evaluating the effect on LDL cholesterol LDL-C and the safety and tolerability of a fixed-dose combination FDC of Laroprovstat and Rosuvastatin in patients who have not previously received lipid-lowering treatment LLT. Laroprovstat is a small molecule developed to reduce LDL-C in the blood, and this Phase III randomized study compares this combination with Laroprovstat alone, Rosuvastatin alone, and placebo in people with hypercholesterolaemia. Participants will be randomly assigned to one of several groups receiving daily oral doses of Laroprovstat, Rosuvastatin at two dose levels, the combination LaroprovstatRosuvastatin at two dose levels, or placebo matching these treatments. The study uses a factorial design and is double-blind, meaning neither participants nor researchers know which treatment is given. Treatment lasts for 8 weeks with assessments focused on changes in LDL-C levels. During the study, participants will attend visits for evaluations including blood tests to measure LDL-C and other cholesterol-related markers such as Apo B, non-HDL cholesterol, and total cholesterol. The main outcome measured is the relative change in LDL-C at 8 weeks. Safety and tolerability will also be monitored throughout. The entire participation period covers the treatment and assessment over the 8-week period.

Age: 18Years - 130YearsAll GendersPhase 3
152 locations
C

Actively Recruiting

Researchers are investigating two treatment approaches for Peripheral Neuropathy in people with Type 2 Diabetes, a common and costly complication causing symptoms like pain, numbness, and tingling. This study aims to better understand how Intraneural Facilitation Therapy INF4 Therapy, a non-invasive manual technique, compares to standard physical therapy in improving neuropathy symptoms and underlying physiological functions. Participants will be randomly assigned to one of two groups one receiving nine 60-minute sessions of INF4 Therapy, which involves specific manual holds to improve blood flow in nerves, and the other receiving nine 60-minute sessions of standard physical therapy focused on muscle stretching, balance, and strengthening exercises. Treatments occur over 6 weeks during 11 study visits, including initial and follow-up assessments. Throughout the study, participants will undergo various tests including pain assessments, heart rate variability monitoring using the Welltory App, vascular imaging, blood oxygen and flow measurements, and blood draws to measure inflammation and blood sugar control. These evaluations occur at several visits to monitor changes and treatment effects. The study will analyze these measures to understand how each therapy impacts nerve function, blood flow, and inflammation over the 6-week period.

Age: 45Years - 85YearsAll GendersPhase Not Applicable
1 location

1-10 of 165

1